Publications by authors named "M M Zeher"
Objective: To characterize the systemic phenotype of primary Sjögren's syndrome at diagnosis by analysing the EULAR-SS disease activity index (ESSDAI) scores.
Methods: The Sjögren Big Data Consortium is an international, multicentre registry based on worldwide data-sharing cooperative merging of pre-existing databases from leading centres in clinical research in Sjögren's syndrome from the five continents.
Results: The cohort included 10 007 patients (9352 female, mean 53 years) with recorded ESSDAI scores available.
Article Synopsis
- * They affect many important things in the body, like how immune cells develop and work, and if they don't function right, it can lead to diseases.
- * This study talks about how miRNAs are made, their role in the immune system, and how they may help understand and treat diseases like lupus and rheumatoid arthritis in the future.
We aimed to answer the question whether the decreased expression of protein kinase C (PKC) isoenzymes in the peripheral blood mononuclear cells (PBMC) of patients with systemic lupus erythematosus (SLE) is inherited or not. For this reason we examined the expression of PKC isoenzymes in a European white girl with acute SLE and in her healthy mother and father simultaneously in summer and winter during one year using western blotting and densitometry. We found that in the father the expression of PKC isoenzymes did not differ from that of eight healthy controls included women and men.
View Article and Find Full Text PDFObjectives: To evaluate the influence of the main immunological markers on the disease phenotype at diagnosis in a large international cohort of patients with primary Sjögren's syndrome (SjS).
Methods: The Big Data Sjögren Project Consortium is an international, multicentre registry created in 2014. As a first step, baseline clinical information from leading centres on clinical research in SjS of the 5 continents was collected.
Article Synopsis
- Autoimmune diseases happen when the body's immune system mistakenly attacks its own healthy cells, leading to long-term damage.
- A type of treatment called autologous hematopoietic stem cell transplantation (AHSCT) helps patients with severe autoimmune diseases who don’t respond to normal treatments by resetting their immune system.
- Although AHSCT can be helpful, it has risks like serious side effects and high chances of complications, but with careful patient selection, it can still be a good option for conditions like multiple sclerosis when other treatments fail.